Catalyst
Slingshot members are tracking this event:
Acorda (ACOR) Plans to Release Top-Line Phase 3 Data Evaluating Tozadenant in Parkinson's Disease in Q1 2018 - Discontinued
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ACOR |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 20, 2017
Occurred Source:
http://ir.acorda.com/investors/investor-news/investor-news-details/2017/Acorda-Discontinues-Tozadenant-Development-Program/default.aspx
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Tozadenant, Parkinson's Disease, Phase 3, Top-line Data Releases, Discontinued, Discontinuation, Terminated, Termination
